Targeted HSP inhibitors have been evaluated in clinical trials against various cancers [121,122,123], but not for GBM, although preclinical studies have demonstrated efficacy of these agents in GBM models when administered alone or in combination with other therapeutics. This evidence concerns the gene HSP90B2P and cancer.